Proteolix, Inc.

225 Gateway Boulevard
South San Francisco
California
94080
United States

Tel: 650-866-6351
Fax: 650-866-6356

About Proteolix, Inc.

Proteolix, Inc. discovers and develops pharmaceutical products that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. Our lead product candidate, carfilzomib (PR-171), is currently in multiple clinical trials to evaluate its safety and efficacy for the treatment of multiple myeloma, lymphoma and certain solid tumor malignancies. In addition, Proteolix is developing next generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class.
Proteolix is privately-held and headquartered in South San Francisco.

25 articles about Proteolix, Inc.

Proteolix, Inc. to Present Preclinical Data on Carfilzomib and PR-957 at the 2009 ACR/ARHP Annual Meeting

10/19/2009
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

6/15/2009
Proteolix, Inc. Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

6/8/2009
Proteolix, Inc. Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 American Society of Clinical Oncology Annual Meeting

6/2/2009
Proteolix, Inc. Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 American Society of Clinical Oncology Annual Meeting

6/1/2009
Proteolix, Inc. to Present Carfilzomib Clinical Data During the 2009 American Society of Clinical Oncology Annual Meeting

5/15/2009
Proteolix, Inc. Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

4/16/2009
Proteolix, Inc. Announces the Appointment of John Scarlett, M.D., President and CEO

2/25/2009
Proteolix, Inc. Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma

12/9/2008
Proteolix, Inc. Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology

12/8/2008
Proteolix, Inc. to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology

11/25/2008
Proteolix, Inc. Presents Solid Tumor Clinical Trial Results for Carfilzomib at EORTC-NCI-AACR International Conference

10/23/2008
Proteolix, Inc. Raises $79 Million in Series C Financing

9/8/2008
Proteolix, Inc. Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma

7/10/2008
Proteolix, Inc. Appoints Thomas Kassberg Executive Vice President of Corporate Development

5/15/2008
Proteolix, Inc. Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors

5/1/2008
Proteolix, Inc. Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer

2/26/2008
Proteolix, Inc. Announces Clinical Results With Carfilzomib to be Reported at American Society of Hematology 2007 Annual Meeting

12/6/2007
Proteolix, Inc. Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib

10/10/2007
The Multiple Myeloma Research Consortium and Proteolix, Inc. Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma

8/15/2007

First
1
2
Next
Last